Status:
COMPLETED
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
Lead Sponsor:
Esanex Inc.
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Solid Tumor Malignancy
Lymphoid Malignancy (Lymphoma and CLL)
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Eligibility Criteria
Inclusion
- Solid tumors or lymphoid malignancies refractory to standard therapy
- measurable disease
- recovery to Grade \< 1 toxicity due to prior adverse event or chemotherapy
- no chemotherapy within 4 weeks of entering study
- Age \> 18 years
- Karnofsy \>= 60%
- Life expectancy \> 3 months
- normal or adequate organ and marrow function
Exclusion
- receiving other investigational agents
- brain metastases
- uncontrolled medical illness
- HIV+ receiving combination antiretroviral therapy
- significant GI disease
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00647764
Start Date
March 1 2008
End Date
September 1 2010
Last Update
May 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bethesda, Maryland, United States, 20892